SUPPLEMENT

Q2 2025 — Investor materials

Q2 2025PDF · 5 pages566 KB
June 20, 2025
2025 Q2 Economic Factors and J&J Announcements
Below is a high-level summary of current macro-economic factors, notable announcements made this quarter, as well
as public commentary made by management during the quarter and recent earnings calls. Any additional information
included herein is provided as phasing considerations and should not be construed as guidance.
Phasing considerations:
In addition to the comments provided during the Q1 earnings call, please note the following:
• 	The impact of Stelara is more pronounced in the first half of 2025 as there was some LoE erosion OUS in the
second half of 2024.
• 	The benefits of restructuring programs in Orthopedics and Surgery are more likely to be seen in the second
half of 2025 given inventory accounting.
• 	The progress of our pipeline warrants both commercial and R&D investment earlier in the year and asset
acquisitions in the second half of 2024 are not anticipated to repeat.
• 	The dilution referenced in the Q1 earnings call related to the acquisition of Intracellular Therapies is
anticipated to be more pronounced in Q2 versus later quarters as sales ramp up and a new indication is
pursued.
• 	For your convenience, as we progress through 2025, we have attached QTD and FY segment P&Ls for 2024.
Macro-economic factors:
• 	Supply Chain / Inflationary Pressures: Elevated inflation rates continued throughout Q2 with April CPI at 2.3%
and May CPI at 2.4%.
• 	Interest Rates: The Federal Funds Rate continues to impact the financing cost of our commercial paper as
well as interest income on our cash position.
• 	Tariffs : in Q1 we noted a 2025 impact of $400M based on tariff information known at that time. Since then,
Joe noted at the Berstein Conference May 28, 2025: “…based on the retaliatory China tariffs that we had in
our $400 million assessment, that probably cuts the $400 million down to $200 million. But that doesn’t
include anything that may come out of Section 232. The Europe tariffs are still somewhat in flux” (Wolk,
2025).
• 	Global Affairs: As described in our Form 10-K risk factors, we have experienced, and expect to continue to
experience, impacts to the Company's business resulting from the Russia-Ukraine war, rising conflict in the
Middle East as well as increasing tensions between the U.S. and China.
• 	Foreign Exchange: We don’t offer guidance or predictions on currency movements, but as highlighted by Joe
during the Q1 2025 earnings call, we utilized the Euro Spot Rate relative to the U.S. dollar as of mid-April of
1.11 to give a sense of the potential impact on Full Year 2025 guidance. The Euro Spot Rate averaged 1.12 in
April, 1.13 in May, and 1.14 through mid-June. As a reminder, our results are based on a basket of currencies, of
which, not all align to the Euro.
Conference participation
J&J conference participation (transcripts and webcasts) throughout the quarter can be found here. Transcripts for
the event below have been attached for your convenience.
• 	BofA Securities 2025 Healthcare Conference: John Reed - Executive Vice President, Innovative Medicine,
Research and Development with Timothy Anderson BofA Securities, Inc. Analyst
• 	2025 RBC Capital Markets Global Healthcare Conference: Joseph Wolk - Chief Financial Officer, Executive
Vice President fireside chat with Shagun Singh - RBC Capital Markets Analyst
• 	Bernstein 41st Annual Strategic Decisions Conference: Joaquin Duato - Chairman and Chief Executive Officer
and Joseph Wolk - Chief Financial Officer, Executive Vice President fireside chat with Lee Hambright -
Managing Director / Senior Analyst, U.S. Medical Devices

-- 1 of 5 --

• 	Goldman Sachs 46th Annual Global Healthcare Conference: Thomas Cavanaugh – Company Group Chairman,
North America Innovative Medicine with Asad Haider – Goldman Sachs Managing Director
Announcements
Press releases issued during the quarter can be found on the J&J Media Center, Innovative Medicine Newsroom,
and MedTech News & Events page.
• 	M&A: N/A
• 	Talc: please visit factsabouttalc.com for the latest company statements
• 	Innovative Medicine:
o 	AKEEGA: Phase 3 AMPLITUDE Study
o 	Bleximenib: EHA Phase1B data
o 	CARVYKTI: 5 Year CARTITUDE-1 and CARTITUDE-4 subgroup
o 	DARZALEX: Favorable ODAC for high-risk smoldering multiple myeloma; Phase 3 PERSEUS and CEPHEUS data
o 	Icotrokinra: Phase 3 ICONIC-Total data
o 	IMAAVY: US FDA Approval
o 	IMBRUVICA: Efficacy data
o 	JNJ-4496: Phase 1b data
o 	Pasritamig: Phase 1 data
o 	TAR-200: AUA curtain raiser; SunRISe-1 Cohort 4 data; SunRISe-1 Cohort 2 data
o 	TECVALYI/TALVEY: RedirecTT-1 data
o 	TREMFYA: Phase 3 APEX PsA data; QUASAR LTE data; Phase 3 ASTRO UC Sub-Q data
o 	Trispecific: Phase 1 data
• 	MedTech:
o 	ORTHO: KINCISE™ 2 System Launch; VOLT Wrist and Proximal Humerus Plating Systems U.S. Launch
o 	OTTAVA: First Cases
o 	VISION: New TECNIS Odyssey Data; TECNIS Odyssey Next-Generation Launch (Europe/Middle East/Canada)
o 	EP: 3-mos Omny-IRE Trial; SOUNDSTAR CRYSTAL™ Launch
o 	Shockwave: IVL-First Real World Data
o 	Surgery: ETHICON 4000 Stapler Launch

-- 2 of 5 --

J&J earnings calls:
• 	Q1 2025 earnings call: Full year 2025 Operational Sales Guidance excluding the COVID-19 Vaccine of $91.6B
- $92.4B or 3.3% - 4.3% and Adjusted Operational Earnings Per Share of $10.50 - $10.70 or 5.2% - 7.2% was
provided on our Q1 2025 Earnings Call. Please see the below 2025 Phasing Considerations slide from the
earnings presentation. For your convenience, the final Q1 2025 earnings transcript and presentation are
attached. Full Q1 2025 earnings call operational commentary and key drivers can be listened to here and the
Q1 2025 10-Q can be found here.
• 	Q2 2024 earnings call: For ease of reference, below are related sales and EPS absolute figures and growth
rates for Q2 2024. Full Q2 2024 operational commentary, key drivers, and one-timers can be listened
to here and the Q2 2024 10-Q can be found here. For your convenience, the final Q2 2024 earnings
transcript and presentation are attached.
o 	Enterprise: $22.4B, 6.6% operational sales growth, 7.2% operational sales growth excluding the COVID-19
Vaccine, and 7.1% adjusted operational sales growth excluding the COVID-19 Vaccine
 	Enterprise sales highlights can be found on page 3 of the final Q2 2024 earnings transcript attached
 	P&L highlights can be found on page 4 and 5 of the final Q2 2024 earnings transcript attached
o 	Innovative Medicine: $14.5B, 7.8% operational sales growth, 8.8% operational sales growth excluding the
COVID-19 Vaccine
 	Innovative Medicine sales highlights can be found on page 3 of the final Q2 2024 earnings transcript
attached
o 	MedTech: $8.0B, 4.4% operational sales growth
 	MedTech sales highlights can be found on page 4 of the final Q2 2024 earnings transcript attached

-- 3 of 5 --



-- 4 of 5 --



-- 5 of 5 --